Clozapine: Brands, Price & Uses in Bangladesh

Clozapine is an atypical (second-generation) antipsychotic reserved for specific, difficult-to-treat clinical situations because of its serious safety profile and the intensive monitoring it requires. Indications below are grouped by strength of evidence.

Established / approved uses

• Treatment-resistant schizophrenia: for severely ill patients with schizophrenia who have not responded adequately to at least two other antipsychotic agents given at adequate doses for an adequate duration.
• Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged, based on history and current clinical state, to be at chronic risk of suicidal behavior.

Off-label / specialist-only uses (not formally approved)

• Psychosis associated with Parkinson's disease that has failed standard measures, occasionally used at low doses under close specialist supervision.
• Treatment-resistant bipolar disorder with prominent psychotic features, as an adjunct under psychiatric specialist care.

Clozapine is not approved for elderly patients with dementia-related psychosis; a boxed warning specifically advises against use in this population because of increased mortality risk.

General principles

Dosing of Clozapine must be individualized, started at a low dose, and titrated slowly, because the risk of orthostatic hypotension, bradycardia, syncope, and seizures is highest during initial dose escalation.

Treatment-resistant schizophrenia and reduction of suicidal behavior (adult dose)

Mandatory absolute neutrophil count (ANC) monitoring

Because of the risk of severe neutropenia (see Precautions and Warnings), Clozapine may only be prescribed and dispensed through a monitoring program that requires a baseline ANC before starting and regular ANC checks throughout treatment (typically weekly for the first 6 months, then every 2 weeks for months 7–12, then monthly thereafter if counts remain normal). Dosing must be interrupted or discontinued according to ANC thresholds established by the monitoring program.

Restarting after an interruption

If Clozapine has been stopped for 2 days or more, it must be restarted at the initial titration dose (12.5 mg once or twice daily) and re-titrated, because of the renewed risk of orthostatic hypotension, bradycardia, and syncope.

Renal or hepatic impairment

Dose reduction and slower titration may be necessary in patients with significant renal or hepatic impairment; such patients should be monitored more closely.

Discontinuation

Whenever possible, Clozapine should be tapered gradually over 1–2 weeks rather than stopped abruptly, to reduce the risk of rebound psychosis and cholinergic rebound symptoms (sweating, headache, nausea, vomiting, diarrhea). If abrupt discontinuation is medically necessary, the patient should be monitored closely.

See Dosage and Administration above for full titration and monitoring detail; see Interaction for dose adjustments needed with certain co-administered drugs.

The most commonly reported adverse effects of Clozapine, occurring in a substantial proportion of patients, include:

• Sedation/drowsiness (very common)
• Hypersalivation (drooling, including at night)
• Tachycardia (fast heart rate)
• Constipation
• Dizziness or lightheadedness, orthostatic hypotension
• Weight gain
• Nausea
• Fever (usually transient, in the first weeks)
• Tremor

Serious adverse effects — including severe neutropenia, seizures, myocarditis/cardiomyopathy, severe gastrointestinal hypomotility (constipation progressing to bowel obstruction), neuroleptic malignant syndrome, and marked metabolic changes (hyperglycemia, dyslipidemia) — are covered in detail under Precautions and Warnings, as they require specific monitoring and action rather than being routine side effects.